1. "2021"
Formats
  1. Journal Article (2507)
  2. Meeting Abstract (1731)
  3. Review (604)
  4. Editorial (358)
  5. Book Section (123)
  6. Correspondence (107)
  7. Guidelines (103)
  8. Research Letter (91)
  9. Miscellaneous (52)
  10. Conference Paper (34)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)

More Groups

People
  1. Alexander Drilon (76)
  2. Miguel-Angel Perales (68)
  3. Sergio Giralt (66)
  4. Robert Motzer (65)
  5. Marc Ladanyi (62)
  6. Monica Morrow (57)

More People

Years
  1. 2021 (5712)
Publications
  1. Journal of Clinical Oncology (471)
  2. Blood (252)
  3. Annals of Oncology (148)
  4. Cancer Research (145)
  5. International Journal of Radiation Oncology, Biology, Physics (145)
  6. Journal of Thoracic Oncology (101)

More Publications

Publishers
  1. Elsevier Inc. (723)
  2. American Society of Clinical Oncology (522)
  3. Springer (381)
  4. Oxford University Press (360)
  5. Nature Publishing Group (344)
  6. American Association for Cancer Research (297)

More Publishers

Results (5712)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/IIa trial of the RNA oligonucleotide STNM01 by EUS-FNI to investigate the safety and efficacy in patients with first-line refractory, unresectable pancreatic cancer
    Meeting Abstract

    Tsuchiya, T.; Fujisawa, T.; Kato, M.; Mizuide, M.; Torisu, Y.; Nishimura, M.; Kurosawa, T.; Tomishima, K.; Takakura, K.; Kutsumi, H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies
    Meeting Abstract

    Niglio, S. A.; da Motta Girardi, D.; Cordes, L. M.; Ley, L.; Mallek, M.; Ortiz, O. S.; Cadena, J.; Diaz, C.; Chalfin, H.; Kydd, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB)
    Meeting Abstract

    Florou, V.; Floudas, C. S.; Maoz, A.; Naqash, A. R.; Hildebrand, G.; Sokol, E.; Frampton, G. M.; Puri, S.; Swami, U.; Wilky, B. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902)
    Meeting Abstract

    Stephens, D. M.; Moseley, A.; Hill, B. T.; Pagel, J. M.; Shadman, M.; Fisch, M. J.; Danilov, A. V.; Ng, D.; Mato, A. R.; Brander, D. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM)
    Meeting Abstract

    Bai, X.; Shoushtari, A. N.; Warner, A. B.; Quach, H.; Cann, C. G.; Zhang, M.; Pallan, L.; Harvey, C.; Si, L.; Tang, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302)
    Meeting Abstract

    Nishihori, T.; Bashir, Q.; Pasquini, M. C.; Martens, M.; Wu, J.; Alsina, M.; Efebera, Y. A.; Gasparetto, C.; Geller, N.; Giralt, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR-inhibitor (FGFRi) erdafitinib
    Meeting Abstract

    Massard, C.; Pant, S.; Iyer, G.; Schuler, M. H.; Witt, O.; Qin, S.; Tabernero, J.; Doi, T.; Hargrave, D. R.; Hammond, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Late morbidity and mortality among survivors of neuroblastoma treated with contemporary therapy: A report from the Childhood Cancer Survivor Study
    Meeting Abstract

    Friedman, D. N.; Goodman, P. J.; Leisenring, W. M.; Diller, L.; Cohn, S. L.; Tonorezos, E. S.; Howell, R. M.; Smith, S. A.; Wolden, S. L.; Neglia, J. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Banerjee, S. N.; Monk, B. J.; Van Nieuwenhuysen, E.; Moore, K. N.; Oaknin, A.; Fabbro, M.; Colombo, N.; O'Malley, D. M.; Coleman, R. L.; Pachter, J. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies
    Meeting Abstract

    Soumerai, J. D.; Jagadeesh, D.; Salman, H. S.; Lossos, I. S.; Asch, A. S.; Reddy, N.; Kenkre, V. P.; Pagel, J. M.; Persky, D. O.; Awan, F. T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save